Nasdaq:GALT
GALECTIN THERAPEUTICS INC
A clinical-stage immuno-oncology biopharma developing Gal-3 based therapeutics to enhance anti-tumor immunity with no current revenue.
Key Metrics
Investment Thesis
Bull Case
Investors may consider this stock for exposure to the promising Galectin-3 immuno-oncology platform which targets a large and growing cancer market. The company has successfully raised substantial capital ($296.2M paid-in capital) to support its pipeline, suggesting management believes in the potential of their proprietary assets.
Bear Case
The stock carries extreme risk given the absence of revenue, massive accumulated deficit, and negative shareholders' equity of $-103.1M indicating deep insolvency if financing dries up. With operating cash flow at -$41.8M and no commercial products, the company faces an imminent liquidity crisis requiring immediate successful fundraising to survive.
About GALECTIN THERAPEUTICS INC
Galectin Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel immuno-oncology therapeutics based on the Galectin-3 (Gal-3) platform. The company targets oncology markets with its lead programs aimed at enhancing immune response against cancer cells. Currently, the firm operates without product revenue, relying entirely on capital raised to fund its extensive research and development activities.
Analysis
Management Discussion
The company reported a net loss of $47.0M for the latest period, driven primarily by operating expenses totaling $42.4M and significant R&D spending of $36.6M. Cash flow from operations was negative $41.8M, offset partially by financing cash flows of $31.2M including revolver proceeds, resulting in a net decrease in cash of $10.5M.
Industry Overview
The biopharmaceutical industry is currently shifting towards immuno-oncology combinations that utilize novel targets like Galectin-3 to improve response rates in difficult-to-treat cancers. Competition is fierce among clinical-stage companies where only those with differentiated mechanisms and solid capital reserves typically reach late-stage trials.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $38.4M | $38.1M | $42.4M |
| Operating Income | $-38.4M | $-38.1M | $-42.4M |
| R&D | $31.7M | $32.1M | $36.6M |
| G&A | $6.6M | $5.9M | $5.9M |
| Stock-Based Comp | $2.9M | $2.3M | $2.4M |
| D&A | $0 | $0 | $0 |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 |
| Interest Expense | $1.0M | $2.8M | — |
| Interest Income | $52.0K | $230.0K | $338.0K |
| Pre-Tax Income | $-38.4M | $-38.1M | $-42.4M |
| Income Tax | $424.0K | $3.0M | $4.6M |
| Continuing Ops | $-38.8M | $-41.1M | $-47.0M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-38.8M | $-41.1M | $-47.0M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-38.8M | $-41.1M | $-47.0M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $20.6M | $27.7M | $17.3M |
| Cash & Equivalents | $18.6M | $25.7M | $15.1M |
| Prepaid Expenses | $2.0M | $2.0M | $2.1M |
| Other Current Assets | $0 | $0 | $0 |
| Long-Term Assets | $733.0K | $490.0K | $243.0K |
| PP&E (Net) | $0 | $0 | $0 |
| Operating Leases | $86.0K | $53.0K | $16.0K |
| Other LT Assets | $647.0K | $437.0K | $227.0K |
| Total Assets | $21.3M | $28.2M | $17.5M |
| Current Liabilities | $13.0M | $15.7M | $35.4M |
| Accounts Payable | $3.9M | $6.4M | $5.7M |
| Current Leases | $40.0K | $46.0K | $19.0K |
| Other Current Liab | $-40.0K | $-46.0K | $21.5M |
| Long-Term Liabilities | $40.5M | $72.8M | $85.2M |
| LT Operating Leases | $66.0K | $20.0K | — |
| Other LT Liab | $40.4M | $72.7M | — |
| Total Liabilities | $53.5M | $88.4M | $120.6M |
| Shareholders' Equity | $-32.2M | $-60.2M | $-103.1M |
| Paid-In Capital | $275.1M | $291.8M | $296.2M |
| Retained Earnings | $-309.6M | $-354.4M | $-401.6M |
| Total L&E | $21.3M | $28.2M | $17.5M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-38.8M | $-41.1M | $-47.0M |
| Non-Cash Adjustments | $3.0M | $3.2M | $2.8M |
| Working Capital Changes | $4.8M | $4.9M | $2.4M |
| Cash from Operations | $-31.1M | $-33.0M | $-41.8M |
| Cash from Investing | $0 | $0 | $0 |
| Cash from Financing | $10.0M | $40.0M | $31.2M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-21.1M | $7.1M | $-10.5M |
| Beginning Cash | $39.6M | $18.6M | $25.7M |
| Ending Cash | $18.6M | $25.7M | $15.1M |
Frequently Asked Questions
How does GALECTIN THERAPEUTICS INC make money?
The company's financials indicate a singular focus on its core drug discovery and development pipeline, specifically within the oncology sector. All operating expenses are directed toward research and development (R&D) and general administrative functions rather than distinct commercial product lines.
What are the main risks for GALT?
1. Complete dependence on external financing due to lack of revenue and negative cash flow from operations. 2. High R&D expenditure ($36.6M) without guaranteed success in clinical trials or regulatory approval. 3. Substantial accumulated deficit ($-401.6M) and negative shareholders' equity increasing dilution risk upon new fundraising.
What is GALT's competitive advantage?
1. Proprietary Galectin-3 platform offering a novel mechanism of action for cancer immunotherapy. 2. Significant cash runway management allowing continued progression of clinical programs despite burn rates. 3. Strategic focus on immuno-oncology combining with checkpoint inhibitors to address high unmet medical needs.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.